|
1.
|
|
9 p, 824.5 KB |
High-throughput RNA sequencing of the T cell receptor alpha and beta chains for simultaneous clonality and biological analyses in Sezary syndrome
/
Blanco, Gonzalo (Hospital del Mar (Barcelona, Catalunya)) ;
López-Aventín, Daniel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Pujol Vallverdú, Ramón M (Hospital del Mar (Barcelona, Catalunya)) ;
Gómez-Llonín, Andrea (Hospital del Mar (Barcelona, Catalunya)) ;
Puiggros, Anna (Hospital del Mar (Barcelona, Catalunya)) ;
López-Sánchez, Manuela (Hospital Clínico Universitario Virgen de la Arrixaca) ;
Estrach, Teresa (Hospital Clínic i Provincial de Barcelona) ;
Garcia Muret, Maria Pilar (Institut d'Investigació Biomèdica Sant Pau) ;
Lopez-Lerma, Ingrid (Hospital Universitari Vall d'Hebron) ;
Servitje, Octavio (Hospital Universitari de Bellvitge) ;
Bellosillo Paricio, Beatriz (Hospital del Mar (Barcelona, Catalunya)) ;
Muro, Manuel (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Espinet, Blanca (Hospital del Mar (Barcelona, Catalunya)) ;
Rabionet, Raquel (Instituto de Salud Carlos III) ;
Gallardo, Fernando (Hospital del Mar (Barcelona, Catalunya))
Previous investigations pointed out a role for antigen stimulation in Sezary syndrome (SS). High-throughput sequencing of the T cell receptor (TR) offers several applications beyond diagnostic purposes, including the study of T cell pathogenesis. [...]
2023 -  10.1002/jcla.24982
Journal of Clinical Laboratory Analysis, Vol. 37 (december 2023)
|
|
|
2.
|
|
2 p, 292.1 KB |
Corrigendum : The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
In the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published. [...]
2023 - 10.3389/fimmu.2023.1332177
Frontiers in immunology, Vol. 14 (2023) , p. 1332177
|
|
|
3.
|
|
12 p, 5.7 MB |
Protein-only Nanoparticles for T Cell Expansion and Activation
/
Fornt Suñé, Marc (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Lázaro Bermejo, Gonzalo (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Gil Garcia, Marcos (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Aran, Andrea (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Garcia-Pardo, Javier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Martí, Mercè (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ventura, Salvador (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
The in vitro expansion and activation of T cells utilizing synthetic nanosized artificial antigen presenting cells (aAPCs) have emerged as a promising technique for cancer treatment. Although diverse nanomaterials have been explored as aAPC scaffolds, protein-only nanoparticles have been largely overlooked, despite their high designability and biocompatibility. [...]
2024 - 10.1021/acsanm.4c00698
ACS applied nano materials, Vol. 7 Núm. 6 (22 2024) , p. 6669-6680
|
|
|
4.
|
|
14 p, 4.2 MB |
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-κB) pathway. [...]
2023 - 10.3389/fimmu.2023.1191782
Frontiers in immunology, Vol. 14 (august 2023)
|
|
|
5.
|
|
15 p, 3.7 MB |
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
/
Botta, Cirino (Clínica Universidad de Navarra) ;
Perez, Cristina (Clínica Universidad de Navarra) ;
Larrayoz, Marta (Clínica Universidad de Navarra) ;
Puig, Noemí (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre) ;
Termini, Rosalinda (Clínica Universidad de Navarra) ;
Goicoechea, Ibai (Clínica Universidad de Navarra) ;
Rodriguez, Sara (Clínica Universidad de Navarra) ;
Zabaleta, Aintzane (Clínica Universidad de Navarra) ;
Lopez, Aitziber (Clínica Universidad de Navarra) ;
Sarvide, Sarai (Clínica Universidad de Navarra) ;
Blanco, Laura (Clínica Universidad de Navarra) ;
Papetti, Daniele Marco (Department of Informatics. University of Milano-Bicocca) ;
Nobile, M.S. (Biostatistics and Bioimaging Centre-B4) ;
Besozzi, Daniela (Biostatistics and Bioimaging Centre-B4) ;
Gentile, Massimo (Department of Oncohematology. "Annunziata" Hospital) ;
Correale, Pierpaolo (Great Metropolitan Hospital "Riuniti" of Reggio Calabria) ;
Siragusa, Sergio (Department of Health Promotion. University of Palermo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Garcia, Maria Esther (Hospital Universitario de Cabueñes (Gijón)) ;
Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
de Arriba, Felipe (Instituto Murciano de Investigación Biosanitaria) ;
Ríos-Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Moraleda, José María (Instituto Murciano de Investigación Biosanitaria) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Hernández, Miguel T. (Hospital Universitario de Canarias (Illes Canàries)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Palomera, Luís (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Pérez-Montaña, Albert (Hospital Universitari Son Espases (Illes Balears)) ;
Goldschmidt, Hartmut (Department of Internal Medicine V. University of Heidelberg) ;
Avet-Loiseau, Hervé (IUC-T Oncopole) ;
Roccaro, Aldo (Department of Hematology. ASST Spedali Civili di Brescia) ;
Orfao, Alberto (Universidad de Salamanca. Departament de Medicina) ;
Martinez-Lopez, Joaquín (Hospital Universitario 12 de Octubre) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mateos, M. V (Hospital Universitario de SalamancaBiomedica de Salamanca (IBSAL). Centro de Investigación del Cancer (IBMCC-USAL. CSIC)) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Martinez Climent, Juan-José (Clínica Universidad de Navarra) ;
Paiva, Bruno (Clínica Universidad de Navarra)
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). [...]
2023 - 10.1038/s41467-023-41562-6
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 5825
|
|
|
6.
|
|
15 p, 2.7 MB |
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
/
Mensali, Nadia (Department of Cellular Therapy. Oslo University Hospital) ;
Köksal, Hakan (Oslo University Hospital) ;
Joaquina, Sandy (Oslo University Hospital) ;
Wernhoff, Patrick (Oslo University Hospital) ;
Casey, Nicholas P. (Oslo University Hospital) ;
Romecín, Paola Alejandra (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Panisello, Carla (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rodríguez, René (Instituto de Salud Carlos III) ;
Vimeux, Lene (Université de Paris) ;
Juzeniene, Asta (Oslo University Hospital) ;
Myhre, Marit R. (Oslo University Hospital) ;
Fåne, Anne (Oslo University Hospital) ;
Castilla-Ramirez, Carolina (Virgen del Rocio University Hospital) ;
Maggadottir, Solrun Melkork (Oslo University Hospital) ;
Duru, Adil Doganay (Nova Southeastern University) ;
Georgoudaki, Anna-Maria (Department of Oncology-Pathology. Karolinska Institutet) ;
Grad, Iwona (Oslo University Hospital) ;
Maturana, Andrés Daniel (Nagoya University) ;
Gaudernack, Gustav (Department of Cancer Immunology. Oslo University Hospital) ;
Kvalheim, Gunnar (Department of Cellular Therapy. Oslo University Hospital) ;
Carcaboso, Angel M. (Institut de Recerca Sant Joan de Déu) ;
De Álava, Enrique (Universidad de Sevilla) ;
Donnadieu, Emma (Université de Paris) ;
Bruland, Øyvind S (University of Oslo) ;
Menendez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Inderberg, Else Marit (Oslo University Hospital) ;
Wälchli, Sébastien (Oslo University Hospital)
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. [...]
2023 - 10.1038/s41467-023-39097-x
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 3375
|
|
|
7.
|
|
10 p, 2.6 MB |
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ;
Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ;
Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ;
Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Locatelli, Franco (Sapienza University of Rome) ;
Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ;
Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urdinguio, Rocío G. (Universidad de Oviedo) ;
Fernandez, A.F. (Universidad de Oviedo) ;
Fraga, Mario F. (Universidad de Oviedo) ;
Bar, Diana (The Edmond and Lily Safra Children's Hospital) ;
Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ;
Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ;
Besser, MichalJ. (Tel Aviv University) ;
Avigdor, Abraham (Sheba Medical Center) ;
Jacoby, Elad (Tel Aviv University) ;
Esteller, M (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 - 10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445
|
|
|
8.
|
|
7 p, 480.5 KB |
Cord Blood Units with High CD3+ Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation
/
Castillo, N. (Banc de Sang i Teixits) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Díaz de Heredia, Cristina (Hospital Universitari Vall d'Hebron) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Ferrá, Christelle (Institut Català d'Oncologia) ;
Canals, Carme (Banc de Sang i Teixits) ;
Elorza, Izaskun (Hospital Universitari Vall d'Hebron) ;
Olivé, Teresa (Hospital Universitari Vall d'Hebron) ;
Badell Serra, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Querol, Sergio (Banc de Sang i Teixits) ;
Universitat Autònoma de Barcelona
Although high absolute lymphocyte count (ALC) early after transplantation is a simple surrogate for immune reconstitution, few studies to date have established the predictive factors for ALC after umbilical cord blood transplantation (UCBT). [...]
2016 - 10.1016/j.bbmt.2016.03.009
Biology of blood and marrow transplantation, Vol. 22 Núm. 6 (january 2016) , p. 1073-1079
|
|
|
9.
|
|
16 p, 3.4 MB |
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
/
Dragon, Anna Christina (Hannover Medical School) ;
Beermann, Luca Marie (Hannover Medical School) ;
Umland, Melina (Hannover Medical School) ;
Bonifacius, Agnes (Hannover Medical School) ;
Malinconico, Chiara (Hannover Medical School) ;
Ruhl, Louisa (Hannover Medical School) ;
Kehler, Patrik (Glycotope GmbH) ;
Gellert, Johanna (Glycotope GmbH) ;
Weiß, Lisa (Glycotope GmbH) ;
Mayer-Hain, Sarah (Glycotope GmbH) ;
Zimmermann, Katharina (Hannover Medical School) ;
Riese, Sebastian (Hannover Medical School) ;
Thol, F. (Department of Hematology. Hannover Medical School) ;
Beutel, Gernot (Hannover Medical School) ;
Maecker-Kolhoff, B. (Department of Pediatric Hematology and Oncology. Hannover Medical School) ;
Yamamoto, Felicitas (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blasczyk, Rainer (Hannover Medical School) ;
Schambach, Axel (Hannover Medical School) ;
Hust, Michael (Department of Medical Biotechnology. Technical University of Braunschweig) ;
Hudecek, Michael (Department of Internal Medicine II. University Hospital of Würzburg) ;
Eiz-Vesper, Britta (Hannover Medical School) ;
Universitat Autònoma de Barcelona
Introduction: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy cells, since "on-target/off-tumor" cytotoxicity is usually intolerable. [...]
2023 - 10.3389/fimmu.2023.1219165
Frontiers in immunology, Vol. 14 (2023) , p. 1219165
|
|
|
10.
|
|
17 p, 2.6 MB |
β-Catenin activity induces an RNA biosynthesis program promoting therapy resistance in T-cell acute lymphoblastic leukemia
/
García-Hernández, Violeta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Arambilet Mobilla, David (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Guillén, Yolanda (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Lobo-Jarne, Teresa (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Maqueda, Maria (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gekas, Christos (Institut Hospital del Mar d'Investigacions Mèdiques) ;
González Miranda, Jessica (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Iglesias, Arnau (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Vega-García, Nerea (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Sentís, Inés (Centre de Regulació Genòmica) ;
Trincado Alonso, Juan Luis, 1987- (Centre de Regulació Genòmica) ;
Márquez-López, Ian (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Camós, Mireia (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Espinosa, Lluís (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Understanding the molecular mechanisms that contribute to the appearance of chemotherapy resistant cell populations is necessary to improve cancer treatment. We have now investigated the role of β-catenin/CTNNB1 in the evolution of T-cell Acute Lymphoblastic Leukemia (T-ALL) patients and its involvement in therapy resistance. [...]
2023 - 10.15252/emmm.202216554
EMBO Molecular Medicine, Vol. 15 Núm. 2 (february 2023)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
